Kymera Therapeutics (KYMR) Competitors $57.21 +0.19 (+0.33%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$57.18 -0.04 (-0.06%) As of 10/10/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. SMMT, RDY, ASND, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, and VRNAShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), Qiagen (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences Qiagen Elanco Animal Health BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Does the media prefer SMMT or KYMR? In the previous week, Summit Therapeutics had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.87 beat Summit Therapeutics' score of 0.62 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in SMMT or KYMR? 4.6% of Summit Therapeutics shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, SMMT or KYMR? Summit Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K22,656.93-$221.32M-$1.01-21.14Kymera Therapeutics$47.07M86.90-$223.86M-$3.47-16.49 Is SMMT or KYMR more profitable? Summit Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% Kymera Therapeutics -616.03%-31.60%-27.12% Which has more risk & volatility, SMMT or KYMR? Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Do analysts rate SMMT or KYMR? Summit Therapeutics currently has a consensus price target of $31.29, indicating a potential upside of 46.54%. Kymera Therapeutics has a consensus price target of $61.26, indicating a potential upside of 7.08%. Given Summit Therapeutics' higher possible upside, equities analysts plainly believe Summit Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 5 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.44Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95 SummaryKymera Therapeutics beats Summit Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.08B$3.38B$6.10B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-16.4921.9785.2726.57Price / Sales86.90462.21612.78132.63Price / CashN/A47.2238.5062.09Price / Book4.4310.2112.726.53Net Income-$223.86M-$52.40M$3.30B$275.96M7 Day Performance-1.19%0.88%0.90%-0.77%1 Month Performance23.83%10.41%6.30%3.67%1 Year Performance27.08%27.28%80.41%37.30% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics1.7801 of 5 stars$57.21+0.3%$61.26+7.1%+32.3%$4.08B$47.07M-16.49170Analyst ForecastSMMTSummit Therapeutics3.0475 of 5 stars$21.16+1.0%$31.29+47.9%+14.7%$15.56BN/A-20.95110Analyst ForecastRDYDr. Reddy's Laboratories2.692 of 5 stars$13.96-1.9%$16.95+21.5%-7.2%$11.87B$334.26B21.1427,811Positive NewsAnalyst ForecastASNDAscendis Pharma A/S3.1067 of 5 stars$191.60-0.2%$244.36+27.5%+60.8%$11.83B$393.54M-37.131,017News CoverageAnalyst ForecastVTRSViatris1.9476 of 5 stars$9.62+1.1%$10.40+8.1%-14.0%$11.10B$14.74B-3.3232,000Analyst ForecastROIVRoivant Sciences3.411 of 5 stars$15.10-0.5%$19.94+32.0%+35.1%$10.36B$23.23M-21.57860Analyst ForecastInsider TradeQGENQiagen4.2984 of 5 stars$43.880.0%$49.69+13.2%+11.5%$9.76B$1.98B25.935,765News CoverageAnalyst ForecastELANElanco Animal Health2.5676 of 5 stars$19.63+0.1%$18.33-6.6%+36.2%$9.74B$4.44B22.829,000Analyst UpgradeBBIOBridgeBio Pharma3.9823 of 5 stars$51.96+3.8%$63.94+23.1%+122.3%$9.57B$221.90M-12.70400Analyst ForecastInsider TradeMRNAModerna4.2436 of 5 stars$25.33+3.4%$41.81+65.1%-52.8%$9.53B$3.24B-3.365,800Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.8186 of 5 stars$106.61-0.1%$109.00+2.2%N/A$9.20B$42.28M-107.6930Positive NewsAnalyst Forecast Related Companies and Tools Related Companies SMMT Competitors RDY Competitors ASND Competitors VTRS Competitors ROIV Competitors QGEN Competitors ELAN Competitors BBIO Competitors MRNA Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
